Systems biology analysis of kinase inhibitor protein target profiles in leukemia treatments
作者： Jacques Colinge , Uwe Rix , Keiryn L. Bennett , Giulio Superti-Furga
DOI: 10.1007/978-3-642-28792-3_9
关键词:
摘要: To be able to understand the mechanisms of action drugs, predict their efficacy, and anticipate potential side-effects is important during drug development. In diseases where genetic background patients modulates treatment response, it might allow personalizing therapy. Substantial progress in proteomic technologies[1] have made possible develop chemical proteomics methods, protein targets a are affinity-purified identified by mass spectrometry[2, 3]. Compound-protein interactions measured biological context as opposed vitro binding assays. That is, drugprotein can not only determined proteome-wide, but also tissue- or cell type-dependent manner.
springer.com
sci-hub.st 参考文章(11)
Curtis T. Keith, Alexis A. Borisy, Brent R. Stockwell, Multicomponent therapeutics for networked systems Nature Reviews Drug Discovery. ,vol. 4, pp. 71- 78 ,(2005) , 10.1038/NRD1609
Uwe Rix, Giulio Superti-Furga, Target profiling of small molecules by chemical proteomics Nature Chemical Biology. ,vol. 5, pp. 616- 624 ,(2009) , 10.1038/NCHEMBIO.216
Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, Lily L. Remsing Rix, Melanie Planyavsky, Nora V. Fernbach, Ines Kaupe, Keiryn L. Bennett, Peter Valent, Jacques Colinge, Thomas Köcher, Giulio Superti-Furga, Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood. ,vol. 110, pp. 4055- 4063 ,(2007) , 10.1182/BLOOD-2007-07-102061
Bruno Domon, Ruedi Aebersold, Mass Spectrometry and Protein Analysis Science. ,vol. 312, pp. 212- 217 ,(2006) , 10.1126/SCIENCE.1124619
Marcus Bantscheff, Arjen Scholten, Albert J.R. Heck, Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discovery Today. ,vol. 14, pp. 1021- 1029 ,(2009) , 10.1016/J.DRUDIS.2009.07.001
Jacques Colinge, Uwe Rix, Keiryn L. Bennett, Giulio Superti-Furga, Systems biology analysis of protein-drug interactions. Proteomics Clinical Applications. ,vol. 6, pp. 102- 116 ,(2012) , 10.1002/PRCA.201100077
Jiannong Li, Uwe Rix, Bin Fang, Yun Bai, Arthur Edwards, Jacques Colinge, Keiryn L Bennett, Jingchun Gao, Lanxi Song, Steven Eschrich, Giulio Superti-Furga, John Koomen, Eric B Haura, A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature Chemical Biology. ,vol. 6, pp. 291- 299 ,(2010) , 10.1038/NCHEMBIO.332
Sebastian Köhler, Sebastian Bauer, Denise Horn, Peter N. Robinson, Walking the Interactome for Prioritization of Candidate Disease Genes American Journal of Human Genetics. ,vol. 82, pp. 949- 958 ,(2008) , 10.1016/J.AJHG.2008.02.013
Charles G. Mullighan, Christopher B. Miller, Ina Radtke, Letha A. Phillips, James Dalton, Jing Ma, Deborah White, Timothy P. Hughes, Michelle M. Le Beau, Ching-Hon Pui, Mary V. Relling, Sheila A. Shurtleff, James R. Downing, BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros Nature. ,vol. 453, pp. 110- 114 ,(2008) , 10.1038/NATURE06866
Bruce D. Gelb, Marco Tartaglia, Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction Human Molecular Genetics. ,vol. 15, pp. R220- R226 ,(2006) , 10.1093/HMG/DDL197